SGLT-2 inhibitors can reduce [Na+]i levels by inhibiting the Na+/H+ exchange (NHE) system (primarily NHE1), reducing Ca2+ leakage, and enhancing mitochondrial Ca2+ concentration to improve heart function and improve outcomes in heart failure [111,112]. Here, SLC5A2 is linked to heart failure.